Robert J. Bauer - Concepedia

Author

Robert J. Bauer

Also Known As

R BAUER, R Bauer, R J Bauer, R. Bauer, R. J. Bauer, R.J Bauer, R.J. Bauer, ROBERT J. BAUER, Robert Bauer, Robert J Bauer

Publications

2.4K

Citations

H-Index

137

Concepts

All Affiliations

XOMA (United States)University of Pittsburgh New England Biolabs (United States)Pinnacle Clinical Research Flometrics (United States)

About

Robert J. Bauer is an author at XOMA (United States) specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	1.2K
2	Natural Sciences	9	9	201
3	Engineering	6	6	343
4	Public Health	1	1	125
5	Social Sciences	1	1	10

Robert J. Bauer

Publications

Citations

H-Index

Page 1

	Year	Citations
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody Kim Papp, Robert Bissonnette, James G. Krueger, Journal of the American Academy of Dermatology Autoimmune DiseaseMedicineImmunologyClinical DermatologyDermatology	2001	176
Acitretin versus etretinate in psoriasis Harald Gollnick, Robert J. Bauer, C. Brindley, Journal of the American Academy of Dermatology InflammationClinical DermatologyPharmacotherapyDermatologyAcitretin Versus Etretinate	1988	143
Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis Robert J. Bauer, Russell L. Dedrick, Mark White, Journal of Pharmacokinetics and Biopharmaceutics	1999	135
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Louis M. Weiner, Joyce L. O'Dwyer, J Kitson, PubMed Breast OncologyImmunologyImmunotherapeuticsPharmacotherapyImmunotherapy	1989	125
NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis Robert J. Bauer CPT Pharmacometrics & Systems Pharmacology EngineeringSimple ExamplesPopulation DynamicPopulation EcologyBiostatistics	2019	125
Inhibition of Endotoxin-Induced Cytokine Release and Neutrophil Activation in Humans by Use of Recombinant Bactericidal/Permeability-Increasing Protein M. A. M. Von Der Möhlen, A N Kimmings, Nancy Wedel, The Journal of Infectious Diseases Neutrophil ActivationEndotoxin LevelsImmunologyRecombinant Endotoxin-binding ProteinCell Death	1995	123
NONMEM Tutorial Part II: Estimation Methods and Advanced Examples Robert J. Bauer CPT Pharmacometrics & Systems Pharmacology Parameter EstimationEngineeringLocalizationPhysiologically-based Pharmacokinetic ModelingPharmacodynamic Modeling	2019	113
Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis Chee M. Ng, Amita Joshi, Russell L. Dedrick, Pharmaceutical Research Pharmacokinetic–pharmacodynamic–efficacy AnalysisMedicineSevere PsoriasisClinical DermatologySkin Pharmacology	2005	89
Effect of Culture Conditions on IgM Antibody Structure, Pharmacokinetics and Activity B. Maiorella, J L Winkelhake, Bryan D. Moyer, Bio/Technology Culture ConditionsIgm Antibody StructureMedicineImmunologyAutoimmunity	1993	69
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas Johann S. de Bono, Anthony W. Tolcher, Andre Forero, Clinical Cancer Research	2004	68

Page 1